AU2023238805A1 - Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease - Google Patents

Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease Download PDF

Info

Publication number
AU2023238805A1
AU2023238805A1 AU2023238805A AU2023238805A AU2023238805A1 AU 2023238805 A1 AU2023238805 A1 AU 2023238805A1 AU 2023238805 A AU2023238805 A AU 2023238805A AU 2023238805 A AU2023238805 A AU 2023238805A AU 2023238805 A1 AU2023238805 A1 AU 2023238805A1
Authority
AU
Australia
Prior art keywords
seq
alpha
recombinant polypeptide
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023238805A
Other languages
English (en)
Inventor
Valentin BRUTTEL
Chi Wang IP
Jörg WISCHHUSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Julius Maximilians Universitaet Wuerzburg
Original Assignee
Julius Maximilians Universitaet Wuerzburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Julius Maximilians Universitaet Wuerzburg filed Critical Julius Maximilians Universitaet Wuerzburg
Publication of AU2023238805A1 publication Critical patent/AU2023238805A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2023238805A 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease Pending AU2023238805A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22164123.6A EP4249506A1 (en) 2022-03-24 2022-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
EP22164123.6 2022-03-24
PCT/EP2023/057682 WO2023180548A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
AU2023238805A1 true AU2023238805A1 (en) 2024-07-18

Family

ID=81384775

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023238805A Pending AU2023238805A1 (en) 2022-03-24 2023-03-24 Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Country Status (12)

Country Link
US (1) US20250205321A1 (https=)
EP (2) EP4249506A1 (https=)
JP (1) JP2025514872A (https=)
KR (1) KR20240162549A (https=)
CN (1) CN119317639A (https=)
AU (1) AU2023238805A1 (https=)
CA (1) CA3250917A1 (https=)
CL (1) CL2024002724A1 (https=)
CO (1) CO2024012329A2 (https=)
IL (1) IL314741A (https=)
MX (1) MX2024011665A (https=)
WO (1) WO2023180548A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024344683A1 (en) * 2023-09-22 2026-04-02 Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3630809A1 (en) 2017-05-23 2020-04-08 Bruttel, Valentin Combinations of mhc class ib molecules and peptides for targeted therapeutic immunomodulation

Also Published As

Publication number Publication date
MX2024011665A (es) 2024-09-27
CA3250917A1 (en) 2023-09-28
EP4249506A1 (en) 2023-09-27
CL2024002724A1 (es) 2025-02-14
CN119317639A (zh) 2025-01-14
WO2023180548A1 (en) 2023-09-28
IL314741A (en) 2024-10-01
EP4499682A1 (en) 2025-02-05
CO2024012329A2 (es) 2024-09-30
JP2025514872A (ja) 2025-05-12
KR20240162549A (ko) 2024-11-15
US20250205321A1 (en) 2025-06-26

Similar Documents

Publication Publication Date Title
JP2020517308A (ja) Ｔｃｒ及びペプチド
JPH10504284A (ja) 抗原パルス化樹状細胞によるｉｎ ｖｉｖｏ Ｔ細胞活性化法
WO2021172596A1 (ja) 免疫制御法、免疫制御用核酸組成物およびその用途
CN112004924A (zh) 增强treg细胞抑制特性的方法
CN102083979A (zh) Hbv表位反应性外源t细胞受体(tcr)及其用途
WO2016095783A1 (zh) 识别eb病毒短肽的t细胞受体
WO2019091347A1 (zh) 识别乙肝病毒(hbv)表面抗原s183-91表位的tcr及其用途
JP2016539635A (ja) 抗原特異的調節性ｔ細胞の誘導方法
JP7606510B2 (ja) Ｅｂｖ－由来抗原に特異的なｔｃｒ構築物
US20250205321A1 (en) Mhc ib-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
Lyu et al. A novel and simple method to produce large amounts of recombinant soluble peptide/major histocompatibility complex monomers for analysis of antigen-specific human T cell receptors
CN117586344B (zh) 靶向flt3-d835突变的抗原肽及其在肿瘤免疫治疗中的应用
US20250222083A1 (en) Mhc ib-mediated myelin-specific immunosuppression as a novel treatment for multiple sclerosis and mog antibody disease
EP4249062A1 (en) Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
EA052620B1 (ru) ОПОСРЕДОВАННАЯ MHC 1b ИНДУКЦИЯ СПЕЦИФИЧЕСКОЙ ДЛЯ АЛЬФАСИНУКЛЕИНА ТОЛЕРАНТНОСТИ В КАЧЕСТВЕ НОВОГО ЛЕЧЕНИЯ ПРОТИВ БОЛЕЗНИ ПАРКИНСОНА
AU2024344683A1 (en) Mhc 1b-mediated alpha-synuclein-specific tolerance induction as a novel treatment for parkinson's disease
Fehlner et al. Murine T cell responses to melittin and its analogs
JP2021511054A5 (https=)
WO2023033124A1 (ja) 免疫制御法、免疫制御用核酸組成物およびその用途
US20250205323A1 (en) Mhc ib-mediated islet-antigen-specific immunosuppression as a novel treatment for type 1 diabetes
WO2025255344A1 (en) Compositions and methods for engineering tregs for treatment of diabetes
CA2103046A1 (en) Suppressor t-cell hybridoma
CA2387391A1 (en) Hu antigen-derived peptides and uses thereof